Partners Steven Baughman and Megan Raymond spoke to Law360 about the implications of their PTAB victories for pharmaceutical giant Novo Nordisk and PTAB practice in general. In “The Biggest PTAB Developments In 2023,” published on December 18, the publication highlighted the firm’s successful effort to thwart generic challenges to two patents protecting Novo Nordisk’s blockbuster drugs Ozempic® and Wegovy® as one of the “biggest” developments in PTAB practice in 2023. The article noted that the wins signified the importance of careful attention to the early stages of PTAB disputes and the overall “high-stakes nature of what PTAB practice has become.”

Read the full article on Law360.